Development of the CogDrisk Tool to Assess Risk Factors for Dementia

Overview

Journal Alzheimers Dement (Amst)

Date 2022 Jul 18

PMID 35845259

Authors

Kaarin J Anstey

Scherazad Kootar

Md Hamidul Huque

Ranmalee Eramudugolla

Ruth Peters

Affiliations

Soon will be listed here.

Abstract

Introduction: We aimed to develop a comprehensive risk assessment tool for Alzheimer's disease (AD), vascular dementia (VaD), and any dementia, that will be applicable in high and low resource settings.

Method: Risk factors which can easily be assessed in most settings, and their effect sizes, were identified from an umbrella review, or estimated using meta-analysis where new data were available.

Results: Seventeen risk/protective factors met criteria for the algorithm to estimate risk for any dementia including age, sex, education, hypertension, midlife obesity, midlife high cholesterol, diabetes, insufficient physical activity, depression, traumatic brain injury, atrial fibrillation, smoking, social engagement, cognitive engagement, fish consumption (diet), stroke, and insomnia. A version for AD excluded atrial fibrillation and insomnia due to insufficient evidence and included pesticide exposure. There was insufficient evidence for a VaD risk score.

Discussion: Validation of the tool on external datasets is planned. The assessment tool will assist with implementing risk reduction guidelines.

Citing Articles

Development and Concurrent Validity of the Short-Form CogDrisk Dementia Risk Assessment Tool.

Anstey K, Huque M, Kootar S, Eramudugolla R, Li M J Prev Alzheimers Dis. 2024; 11(6):1751-1758.

PMID: 39559886 PMC: 11573794. DOI: 10.14283/jpad.2024.108.

Modifiable dementia risk associated with smaller white matter volume and altered 1/f aperiodic brain activity: cross-sectional insights from the LEISURE study.

Pace T, Levenstein J, Anijarv T, Campbell A, Treacy C, Hermens D Age Ageing. 2024; 53(11).

PMID: 39523601 PMC: 11551051. DOI: 10.1093/ageing/afae243.

A single risk assessment for the most common diseases of ageing, developed and validated on 10 cohort studies.

Huque M, Kootar S, Kiely K, Anderson C, van Boxtel M, Brodaty H BMC Med. 2024; 22(1):501.

PMID: 39482675 PMC: 11526665. DOI: 10.1186/s12916-024-03711-6.

Plasma proteomics for risk prediction of Alzheimer's disease in the general population.

Yang S, Ye Z, He P, Zhang Y, Liu M, Zhou C Aging Cell. 2024; 23(12):e14330.

PMID: 39252463 PMC: 11634738. DOI: 10.1111/acel.14330.

Social Environment, Lifestyle, and Genetic Predisposition With Dementia Risk: A Long-Term Longitudinal Study Among Older Adults.

Chen S, Chen S, Hanewald K, Si Y, Bateman H, Li B J Gerontol A Biol Sci Med Sci. 2024; 79(7).

PMID: 38733088 PMC: 11184450. DOI: 10.1093/gerona/glae128.

References

Anstey K, Cherbuin N, Herath P . Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention. Prev Sci. 2013; 14(4):411-21. PMC: 3696462. DOI: 10.1007/s11121-012-0313-2. View

Peters R, Breitner J, James S, Jicha G, Meyer P, Richards M . Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors. Alzheimers Dement (N Y). 2021; 7(1):e12202. PMC: 8655351. DOI: 10.1002/trc2.12202. View

Schiepers O, Kohler S, Deckers K, Irving K, ODonnell C, van den Akker M . Lifestyle for Brain Health (LIBRA): a new model for dementia prevention. Int J Geriatr Psychiatry. 2017; 33(1):167-175. DOI: 10.1002/gps.4700. View

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396(10248):413-446. PMC: 7392084. DOI: 10.1016/S0140-6736(20)30367-6. View

Anstey K, Kootar S, Huque M, Eramudugolla R, Peters R . Development of the CogDrisk tool to assess risk factors for dementia. Alzheimers Dement (Amst). 2022; 14(1):e12336. PMC: 9275658. DOI: 10.1002/dad2.12336. View

Stephan B, Pakpahan E, Siervo M, Licher S, Muniz-Terrera G, Mohan D . Prediction of dementia risk in low-income and middle-income countries (the 10/66 Study): an independent external validation of existing models. Lancet Glob Health. 2020; 8(4):e524-e535. PMC: 7090906. DOI: 10.1016/S2214-109X(20)30062-0. View

Kivipelto M, Solomon A . Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence. Acta Neurol Scand Suppl. 2006; 185:50-7. DOI: 10.1111/j.1600-0404.2006.00685.x. View

Joas E, Backman K, Gustafson D, Ostling S, Waern M, Guo X . Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension. 2012; 59(4):796-801. DOI: 10.1161/HYPERTENSIONAHA.111.182204. View

Peters R, Dodge H, James S, Jicha G, Meyer P, Richards M . The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?. Alzheimers Dement. 2021; 18(3):507-512. DOI: 10.1002/alz.12393. View

10.

Austin P, Lee D, DAgostino R, Fine J . Developing points-based risk-scoring systems in the presence of competing risks. Stat Med. 2016; 35(22):4056-72. PMC: 5084773. DOI: 10.1002/sim.6994. View

11.

Kuzma E, Lourida I, Moore S, Levine D, Ukoumunne O, Llewellyn D . Stroke and dementia risk: A systematic review and meta-analysis. Alzheimers Dement. 2018; 14(11):1416-1426. PMC: 6231970. DOI: 10.1016/j.jalz.2018.06.3061. View

12.

Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J . Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006; 5(9):735-41. DOI: 10.1016/S1474-4422(06)70537-3. View

13.

Anstey K, Ee N, Eramudugolla R, Jagger C, Peters R . A Systematic Review of Meta-Analyses that Evaluate Risk Factors for Dementia to Evaluate the Quantity, Quality, and Global Representativeness of Evidence. J Alzheimers Dis. 2019; 70(s1):S165-S186. PMC: 6700718. DOI: 10.3233/JAD-190181. View